Company intelligence / Profile preview

GP40021

Kurume, Fukuoka, Japan

Ownership: Private
Employees: ~50
Development stage: Other

Overview

GreenPeptide is a clinical-stage biotechnology company based in Japan that specializes in the development of personalized peptide vaccines for cancer immunotherapy. The company's core technology involves identifying and utilizing specific peptides that match a patient's human leukocyte antigen (HLA) type and pre-existing immunity to stimulate a targeted T-cell response. Their lead programs have focused on challenging indications such as glioblastoma and prostate cancer. GreenPeptide aims to provide precision medicine solutions by tailoring treatments to the individual immunological profile of each patient.

Therapeutic areas: Oncology
Modalities: PeptidesVaccineCancer vaccine
Industry: Biotech

Partnerships

FujifilmBrightPath Biotherapeutics

Beyond the preview

Go deeper on GP40021.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GP40021.

Explore the full profile